Truist Financial Begins Coverage on BioNTech (NASDAQ:BNTX)

Truist Financial started coverage on shares of BioNTech (NASDAQ:BNTXGet Free Report) in a research note issued to investors on Friday, MarketBeat reports. The brokerage set a “buy” rating and a $172.00 price target on the stock. Truist Financial’s price target points to a potential upside of 40.01% from the company’s previous close.

Several other analysts have also recently weighed in on BNTX. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and raised their price objective for the company from $90.00 to $137.00 in a research report on Friday, November 8th. UBS Group increased their price objective on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. dropped their target price on BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a research report on Tuesday, November 26th. Deutsche Bank Aktiengesellschaft increased their price target on shares of BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, September 19th. Finally, Evercore ISI upgraded shares of BioNTech from an “in-line” rating to an “outperform” rating and boosted their price objective for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $142.72.

Check Out Our Latest Stock Analysis on BioNTech

BioNTech Price Performance

NASDAQ BNTX opened at $122.85 on Friday. The firm’s 50-day simple moving average is $114.30 and its two-hundred day simple moving average is $103.44. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The company has a market cap of $29.45 billion, a PE ratio of -58.50 and a beta of 0.18.

BioNTech (NASDAQ:BNTXGet Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The company had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech’s revenue was up 38.9% compared to the same quarter last year. During the same period last year, the business earned $0.73 earnings per share. Research analysts predict that BioNTech will post -3.72 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

A number of large investors have recently bought and sold shares of the business. Planning Capital Management Corp increased its position in BioNTech by 45,000.0% during the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after buying an additional 450 shares in the last quarter. Blue Trust Inc. lifted its stake in BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after acquiring an additional 388 shares during the period. GAMMA Investing LLC boosted its holdings in BioNTech by 21.7% in the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after purchasing an additional 111 shares during the last quarter. Clear Harbor Asset Management LLC purchased a new stake in shares of BioNTech in the third quarter worth about $210,000. Finally, Probity Advisors Inc. purchased a new position in shares of BioNTech during the 3rd quarter valued at approximately $216,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

(Get Free Report)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

Further Reading

Analyst Recommendations for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.